Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks Nivolumab's impact on advanced stomach and esophageal cancers

NCT ID NCT07663786

Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolumab and what factors affect their outcomes. The goal is to understand how well the drug works outside of clinical trials, in everyday hospital settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nivolumab
What this could lead to
If successful, this could show how well nivolumab works in everyday practice for advanced stomach and esophageal cancers, helping doctors make better treatment decisions.
What could go wrong
This is an observational study using existing data, not a controlled trial. It cannot prove cause and effect, and results may be influenced by factors like patient selection or missing information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 726 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults in the Netherlands diagnosed with HER2-negative unresectable advanced or synchronous metastatic Esophageal Adenocarcinoma (EAC), Gastro-esophageal Junction Adenocarcinoma (GEJAC), or Gastric Adenocarcinoma (GAC) diagnosed between 01-Aug-2022 and 31-Jul-2024

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Registered in the Netherlands Cancer Registry (NCR) * Diagnosed with Esophageal Adenocarcinoma (EAC), Gastro-esophageal Junction Adenocarcinoma (GEJAC), or Gastric Adenocarcinoma (GAC) from 01-Aug-2022 to 31-Jul-2024 * Age ≥18 years at diagnosis * Unresectable advanced (cT4B) or synchronous metastatic (cM1) disease at diagnosis * (Cohort 2) Programmed cell Death Ligand 1 (PD-L1) CPS ≥5 * (Cohort 3) Received nivolumab as part of first-line treatment Exclusion Criteria: * Neuro-endocrine carcinomas or non-epithelial cancers of esophagus/ gastroesophageal junction /stomach * Positive HER2 expression

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal adenocarcinoma Gastric adenocarcinoma Gastro-esophageal junction adenocarcinoma

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.